NCT04347239 - Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19 | Biotech Hunter

Enrollment

484

Participants

Timeline

Start Date

April 16, 2020

Primary Completion Date

October 24, 2021

Study Completion Date

June 15, 2022

Conditions

Coronavirus Disease 2019

Interventions

DRUG

Placebo

DRUG

Leronlimab (700mg)

Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

Trial Locations (18)

10467

Montefiore Medical Center, The Bronx

11229

New York Community Hospital of Brooklyn, Brooklyn

27103

Novant Health, Winston-Salem

30501

Center for Advanced Research & Education (CARE), Gainesville

33612

James A. Haley Veterans' Hospital, Tampa

35010

Advanced Cardiovascular, LLC, Alexander City

43215

Ohio Health, Columbus

75204

Baylor Scott & White Research Institute, Dallas

77030

Baylor College of Medicine, Houston

University of Texas, Houston

90095

UCLA, Los Angeles

92835

St. Jude Medical Center, Fullerton

97239

Oregon Health and Sciences University, Portland

97330

Good Samaritan Hospital Corvallis, Corvallis

02215

Beth Israel Deaconess Medical Center, Boston

07052

St. Barnabas, Livingston

07962-1905

Atlantic Health System Hospital, Morristown

07666

Holy Name Medical Center, Teaneck